Home

Triple refractory multiple myeloma

Niedrige Preise, Riesen-Auswahl. Kostenlose Lieferung möglic Triple-Refractory Multiple Myeloma Symptoms New symptoms may be a clue that your multiple myeloma treatment isn't working anymore and you have become resistant to treatment. They can include: 2  Bone pain, especially in the back or rib The current approaches to the treatment of triple-class refractory disease are limited and include conventional chemotherapy, salvage autologous stem cell transplantation, and recycling previous regimens, each of which have generally had short-lived efficacy Despite the availability of new treatments, most patients with multiple myeloma will become refractory to the therapies that currently comprise the hematologic standard of care for the malignancy, including proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies If you are relapsed/refractory to the 3 most common types of medicines for multiple myeloma, there is a specific name for that. Your disease would be called triple-class refractory. You may have heard of the most common types, which are 4: Proteasome inhibitors

Keywords: Autologous stem cell transplantation, Monoclonal antibodies, Relapsed myeloma, Selinexor, Triple-class refractory Introduction Multiple myeloma (MM), characterized by the expansion of malignant plasma cells in the bone marrow,1 accounts for w1% of all malignancies and 10% of hematologic malignancies.2 In the pas

Myelom - bei Amazon

New Class of Drug Appears to Extend Survival in Patients With Triple-Refractory Multiple Myeloma - Cancer Therapy Advisor July 30, 2020 New Class of Drug Appears to Extend Survival in Patients With.. The FDA granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone for adults with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one CD38-directed monoclonal antibody Home » Cancer Topics » Multiple Myeloma Publish Date July 30, 2020 New Class of Drug Appears to Extend Survival in Patients With Triple-Refractory Multiple Myeloma

It reflects that triple-class refractory multiple myeloma is a challenge for treatment and characterized by a much shorter duration of progression-free survival. Sometimes you can see that there's.. A Melflufen Update in Multiple Myeloma Myeloma Crowd published a post three months ago about the work of the Swedish company Oncopeptides in treating triple refractory multiple myeloma (patients whose myeloma had broken through prior treatment with an immunomodulator, a proteasome inhibitor and Darzalex)

Triple-Refractory Multiple Myeloma: Overview and Mor

  1. People with triple class relapsed-refractory multiple myeloma and extramedullary disease represent the largest group of myeloma patients with unmet medical needs today, the company reported in an in-house trial presentation
  2. Deepu Madduri, MD: In regard to the treatment landscape for patients with triple-refractory or relapsed multiple myeloma—meaning if they've progressed after an IMiD [immunomodulatory imide drug], a proteasome inhibitor, an anti-CD38 monoclonal antibody—we know, based on the MAMMOTH study, these patients have an overall survival rate of less than 9.2 months
  3. Multiple myeloma (MM) is a chronic disease for which no curative treatment exists. Patients refractory to both proteasome inhibitors and immuno-modulatory drugs (IMiDs) have a median overall survival estimate of 9 months and progression-free survival (PFS) estimates of 5 months at best (Kumar et al, 2012).. CD38 is a 45 kDa type II transmembrane glycoprotein (Deaglio et al, 2007), which is.
  4. The Triple-refractory Multiple Myeloma epidemiology covered in the report provides historical as well as forecasted Triple-refractory Multiple Myeloma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030
  5. istration for melflufen's accelerated approval for triple-refractory multiple myeloma patients, or those who failed to respond to treatment with at least one immunomodulatory drug, one proteasome inhibitor, and one anti-CD38 monoclonal antibody

Treatment Options for Triple-class Refractory Multiple Myelom

Refractory Multiple Myeloma. Refractory is another word for resistant. Refractory myeloma is cancer that develops resistance to treatment or does not respond to it at all. There are two types of refractory myeloma: Relapsed and refractory myeloma: Myeloma that initially responds to treatment but then stops responding to it after a time or. The Triple-refractory Multiple Myeloma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Triple-refractory Multiple Myeloma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology Global Triple-refractory Multiple Myeloma Market: Regional Segment Analysis This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth

1. Br J Haematol. 2016 Aug;174(3):473-7. doi: 10.1111/bjh.13776. Epub 2015 Oct 12. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach With Your Help, We Will Advance Our Research Aimed at Finding A Cure. Your Contribution Supports Programs & Services Designed To Educate & Empower Patients

Myeloma Program University of California, San Francisco Medical Center San Francisco, California. Triple-Class Refractory: Selecting BCMA-Directed Therapy? This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical Care Options, LLC and the International Myeloma Foundation Daratumumab has been heralded a game changer in Multiple Myeloma (MM) as it drives strong responses, both as a monotherapy and in combination with backbone regimens. Daratumumab is slowly edging towards use as a frontline therapy, but recent approvals currently place it firmly in the relapsed setting

In this trial, 26% of the patients with penta-exposed, triple-class refractory myeloma who received oral selinexor, a first-in-class XPO1 inhibitor, with dexamethasone twice weekly had a partial. patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior therapies including an Not triple-refractory (N=57) 11.2 (5.4, 17.1 Multiple Myeloma in 2020 . This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical Care Options, LLC and the International Myeloma Foundation. Disclosures. Jesús F. San-Miguel, MD, PhD, has disclosed that he has receive The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. Refractory status (not triple refractory vs triple- or quad-refractory vs penta-refractory): 11.2 months (95% CI, 5.4-17.1).

Triple-Class Refractory Multiple Myeloma - MYeloma Channe

  1. The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of.
  2. Prabhala, R. H. et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115 , 5385-5392 (2010)
  3. Key Statistics About Multiple Myeloma. Multiple myeloma is a relatively uncommon cancer. In the United States, the lifetime risk of getting multiple myeloma is 1 in 132 (0.76%). The American Cancer Society's estimates for multiple myeloma in the United States for 2021 are: About 34,920 new cases will be diagnosed (19,320 in men and 15,600 in.
  4. Among the patients being enrolled are those with heavily pre-treated, triple refractory and penta-exposed multiple myeloma, including those with extra-medullary (outside of the bone marrow) and non-secretory (do not secrete detectable myeloma proteins) disease. About Multiple Myeloma Multiple myeloma is the second most common blood cancer with.
  5. A retrospective analysis suggests improved survival outcomes with selinexor plus dexamethasone compared with standard treatments in triple-class relapsed or refractory multiple myeloma (RRMM). Real-World Outcomes of Triple-Class Refractory, Penta-Exposed RRMM - Journal of Oncology Navigation & Survivorshi

Overall survival of patients with triple-class refractory

  1. Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joseph MikhaelAbstractThe advent of new, more effective, and less toxic therapies has revolutionized the management of multiple myeloma in the past decade. Despite the availability of new treatments, the majority of patients with multiple myeloma will become refractory to the therapies.
  2. A significant portion of patients with triple-refractory myeloma have disease that is refractory to the five therapies listed above. As previously stated, these patients have myeloma that is characterized as rapidly progressing with median OS values of only roughly 1.5-3 months
  3. A previous dose finding study showed selinexor with dexamethasone in triple-refractory multiple myeloma patients resulted in response for a portion of the patients. The Selinexor Treatment of Refractory Myeloma (STORM) part 2 study further evaluates treatment of triple refractory patients with selinexor and dexamethasone
  4. The FDA approved melphalan flufenamide (Pepaxto; melflufen) plus dexamethasone for adults with triple-refractory multiple myeloma. The FDA has approved melphalan flufenamide (Pepaxto; melflufen) plus dexamethasone for adults with multiple myeloma whose disease is refractory to 1 or more of each type of agent: proteasome inhibitor (PI.
  5. Patients with relapsed/refractory multiple myeloma previously exposed to immunomodulatory agents, protease inhibitors, and anti-CD38 antibodies have poor outcomes with subsequent therapy using previously approved regimens, with expected response rates in the 26% to 31% range, PFS in the two- to four-month range, and overall survival less.
  6. The treatment of multiple myeloma has changed drastically in the past decade with the incorporation of novel agents into therapeutic strategies. inhibitor, and an anti-CD38 antibody, and all were refractory to their last regimen. 107 (84%) of 128 patients were triple-refractory (refractory to an immunomodulatory agent, proteasome inhibitor.
  7. Myeloma is the fifteenth leading cause of cancer death in the United States. The death rate was 3.2 per 100,000 men and women per year based on 2014-2018 deaths, age-adjusted. The percent of myeloma deaths is highest among people aged 75-84

Patients with relapsed/refractory myeloma have a median overall survival of only 9.2 months in triple-refractory [disease] and only 5.6 months in penta-refractory. In this study, we know that the median PFS is at least a full year and we still haven't even reached a median PFS after a median duration of follow-up of 12.4 months, Madduri. Topline results show a 26% response rate in a Phase 2 clinical trial evaluating Ygalo (melflufen) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the therapy's developer, Oncopeptides, announced.. These data will support a request for accelerated approval for Ygalo to treat people with triple-refractory multiple myeloma in the U.S., the company. Overview. Several abstracts addressing challenging-to-treat, refractory multiple myeloma were presented at the Virtual Edition of the 25th EHA Annual Congress.Subgroups of interest included heavily pretreated patients, those with renal impairment, and those who were refractory to agents in more than 1 class of therapy Six out of 15 patients with triple-refractory multiple myeloma achieved a response after receiving 60 millicurie (a unit of radioactivity) of CLR 131. These patients were enrolled in part A of the CLOVER-1 study. Triple-class refractory disease is resistant to treatment with immunomodulatory agents, proteasome inhibitors and anti-CD38 targeted.

In multiple myeloma, relapse is inevitable due to the genomic evolution that is characteristic of the disease. With each relapse or with the development of refractory disease, fewer patients achieve a deep response to anti-myeloma therapy. In fact, a study showed that the number of patients who achieved a deep response decreased to less than 5%. The therapy, administered intravenously (into the vein), is intended for patients with triple-refractory multiple myeloma who failed to respond to treatment with at least one immunomodulatory drug (IMiD), one proteasome inhibitor, and one anti-CD38 monoclonal antibody Celgene Corp.'s Revlimid (lenalidomide) is the top-selling drug approved for multiple myeloma by far and will remain a blockbuster long after generics become available in 2022. It will maintain such a strong presence, in fact, that the top brand in 2026 will generate a fraction of Revlimid's peak sales. Datamonitor Healthcare's latest multiple myeloma market forecast suggests that drug sales. The promise of the alkylating agent melphalan for the treatment of multiple myeloma (MM) was first documented in 1958 where reduction in tumor burden was noted in three of six patients. 1 In 2018 to melflufen and dexamethasone on March 1 for patients with MM who have received four or more lines of therapy and have triple refractory disease..

A New and Different Approach to Treat Triple Refractory

Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial Wednesday, April 22, 2020 Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the therapy's developer. Patients with relapsed/refractory multiple myeloma previously exposed to immunomodulatory agents, protease inhibitors, and anti-CD38 antibodies have poor outcomes with subsequent therapy using previously approved regimens, with expected response rates in the 26% to 31% range, PFS in the 2- to 4-month range, and overall survival less than 9. Read Re‐challenging with anti‐CD38 monotherapy in triple‐refractory multiple myeloma patients is a feasible and safe approach, British Journal of Haematology on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips Ide-cel provides an attractive option for treatment of triple-class exposed relapsed/refractory multiple myeloma. Munshi said 84% of the patients had triple-refractory disease and 94% were. The study will assess the feasibility of generating these Advanced Therapy Investigational Products (ATIMPs), the safety of administering the CAR T cells (either BCMA alone or coexpressed with CD19), and how well the CAR T cells will engraft, expand and persist following administration in patients with triple refractory multiple myeloma

Triple-Class Exposed Relapsed and Refractory Multiple Myelom

The BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (previously known as bb2121) induced responses in nearly three-quarters of patients with relapsed/refractory multiple myeloma, according to results from the phase II KarMMa trial, which were presented by Jesus San-Miguel, MD, PhD, as part of EHA25 Virtual, the 25th European Hematology Association Annual. The response rate was 36% (16/45) at doses of 3-12 mg; at ≤1.6 mg (n=27), there was 1 response at 0.8 mg in a patient with low baseline soluble BCMA (sBCMA). With earlier dose escalation with 9 mg, the response rate was 83% (5/6, 3 PRs, 2 VGPRs), with 4/5 responders being triple refractory and 1 DLT of grade 3 CRS in this group. Across the. The researchers analyzed CD38 expression of multiple myeloma cells taken from 102 patients prior to undergoing treatment with 16 mg/kg daratumumab as part of a phase II clinical trial. According to the analysis, all cells expressed CD38, but expression levels varied greatly among patients. Thirty patients of the 102 achieved a partial response.

Overall Survival of Triple Class Refractory, Penta-Exposed

The FDA has approved idecabtagene vicleucel (ide-cel; formerly bb2121; Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody. 1 Ide-cel represents the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor. A novel chimeric antigen receptor T-cell therapy induced responses in the first 12 evaluable patients with relapsed or refractory multiple myeloma treated in a phase 1 dose-escalation trial New Jersey, United States,- The Dry Scroll Vacuum Pumps Market study provides details of market dynamics affecting the market, market size, and segmentation, and casts a shadow over the major market players by highlighting the favorable competitive landscape and successful trends over the years. This market report presents the detailed profile of major industry players and their upcoming. Multiple myeloma (MM), is a plasma cell neoplasia, characterized by an abnormal proliferation of aberrant plasma cells in the bone marrow and the production of a clonal immunoglobulin [1]. triple-refractory' (refractory to 1 anti-CD38 mAb and not both of a proteasome inhibitor and an IMiD), 'triple- and quad-.

CLR 131 Fares Well in Phase 2 Triple-refractory Multiple

In study I we could show that two heavily pretreated, triple refractory multiple myeloma patients, who received Daratumumab treatment and progressed, could be re-challenged with the same drug. We observed that the recurring multiple myeloma cells showed normal CD38 expression after a short treatment interruption 1.1. Multiple Myeloma. Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells and represents around 10% of diagnosed hematological malignancies in developed countries [].It is characterized by the expansion of clones carrying one or more genetic alterations within the bone marrow [].Although MM is a genetically heterogeneous disease [], a common feature of malignant plasma. A total of 140 patients who had received at least 3 prior treatment regimens for multiple myeloma including an IMiD, a PI, and an anti-CD38 antibody and were refractory to their last treatment regimen, were enrolled in the study. However, only 128 patients received infusion with ide-cel

Treatment Advances in Triple-Class Refractory/Relapsed Myelom

Source: Dr Jesus Berdeja & Asco. These deepening responses will be seen as highly promising in what on a cross-trial basis looks to be the most efficacious anti-BCMA Car-T project in relapsed/refractory multiple myeloma. JNJ-4528 is now in the phase III Cartitude-2 study, and of course efficacy in a larger trial of this sort is likely to fall off On February 26, 2021, the FDA accelerated the approval of melphalan flufenamide (Pepaxto; Oncopeptides AB), an alkylating drug, for the treatment, in combination with dexamethasone, of adults with relapsed or refractory multiple myeloma who have received ≥4 lines of therapy and whose disease is triple-refractory to ≥1 proteasome inhibitors, 1 immunomodulatory drug, and 1 CD-38-directed. Among heavily pretreated patients with relapsed or refractory multiple myeloma, idecabtagene vicleucel (ide-cel) - a chimeric antigen receptor (CAR)-T cell therapy - may induce a response, although it carries a high rate of adverse events (AEs), according to research published in The New England Journal of Medicine.. Although many novel treatments have entered the multiple myeloma.

New Class of Drug Appears to Extend Survival in Patients

Disparities in Multiple Myeloma Hem/Onc Roundup: Experts Discuss BCMA CAR T for Relapsed/Refractory MM, and More Here you will find the latest news, expert commentary, and research papers on a wide range of topics related to Multiple Myeloma Melflufen Combo Earns FDA Priority Review for Triple-refractory Myeloma. Patient Ahead September 4, 2020. plus dexamethasone for people with relapsed or refractory multiple myeloma (RRMM). The new drug application was submitted in July and based on promising data from the HORIZON Phase 2 trial (NCT02963493).. Bispecific antibodies are showing promise in patients with hematologic malignancies, notably relapsed or refractory multiple myeloma. Results from studies of 3 bispecific antibodies were presented at ASH 2020, showing deep and durable responses. In addition, 6 of 9 (67%) patients with triple-refractory disease had a response, and the 2. in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics . INTRODUCTION ABSTRACT . CONCLUSION PATIENT RESPONSE - DL2 . Amrita Krishnan, MD, FACP 1, Prashant Kapoor, MD2, Joycelynne Palmer, PhD1, NiChun Tsai, MS1*, Shaji Kumar, MD2, Sagar Lonial The FDA noted that approval of ide-cel for multiple myeloma is based on data from a multicenter study that involved 127 patients with relapsed/refractory disease who had received at least three.

New Class of Drug Appears to Extend Survival in Patients

FDA Approves Pepaxto for Triple-Refractory Multiple Myelom

GlobeNewswire. Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth With A Gamut of Pharma Companies Involved Worldwide. The Multiple Myeloma pipeline is majorly thriving owing to the several different companies developing novel and sophisticated blockbuster drugs, increasing R&D, increasing global prevalence, better awareness and appropriate diagnosis in patients.Los Angeles, USA. Multiple myeloma remains an incurable disease despite great advances in its therapeutic landscape. Increasing evidence supports the belief that immune dysfunction plays an important role in the disease pathogenesis, progression, and drug resistance. Recent efforts have focused on harnessing the immune system to exert anti-myeloma effects with encouraging outcomes The use of combinations of new drugs with different mechanisms of action for the treatment of multiple myeloma (MM) in the last decade has dramatically prolonged life expectancy of patients. 1 These combinations, triplet or even quadruplet regimens, of proteasome inhibitors (PIs), immunomodulatory agents (IMIDs) and monoclonal antibodies (MoAbs) have emerged as game-changer agents, 2,3. multiple myeloma (IMWG*) ECOG 0-2 ≥ 3 prior lines of anti-myeloma therapy PI + IMiD-refractory Failed anti-CD38 Belamaf 2.5 mg/kg Q3W N = 97 Belamaf 3.4 mg/kg Q3W N = 99 R *Confirmation of MM based on International Myeloma Working Group criteri

Establishing a Treatment Plan for Triple-Class Refractory

Saad Usmani and colleagues1 present the long term follow-up of pooled data from two phase 2 studies (GEN-501 and SIRIUS) including 148 heavily pretreated patients given daratumumab monotherapy for relapsed and refractory multiple myeloma. Usmani and colleagues report that the proportion of patients with overall response rate was 30·4% (95% CI 23·1-38·5%) with a median progression-free. The addition of novel therapies, such as CD38 monoclonal antibodies (moAbs), to IMiD- and PI-backbone regimens has improved outcomes in patients with relapsed and refractory multiple myeloma (RRMM). 1 -5 However, patients who become refractory to existing therapies have a very poor prognosis, with a median overall survival (OS) ranging from 5. Selinexor plus dexamethasone resulted in objective treatment responses in patients with triple-refractory multiple myeloma (MM), according to a study published in The New England Journal of Medicine. The open-label, phase IIb STORM study included 122 (median age, 65 years) U.S. and European patients Triple Refractory Multiple Myeloma Market DelveInsight's Triple-refractory Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast-2030 report. Higher Risk Chronic Myelomonocytic Leukemia Marke myeloma including this anti‐SLAMF7 monoclonal antibody, a histone deacetylase inhibitor, and an XPO1 inhibitor. Taking Aim at an Ideal Therapeutic Target in Relapsed/Refractory Multiple Myeloma ©2020 MediCom Worldwide, Inc

Multiple Myeloma in Dogs & Cats – A Cancer of the Immune

Meflufen for Myeloma - The Myeloma Crow

REGN5458 monotherapy is being investigated in an open-label, Phase 1/2 dose-escalation trial in patients with R/R multiple myeloma who are at least triple refractory to existing therapeutic. The primary objectives of the study are: Phase 1: To assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended Phase 2 dose regimen (RP2DR) of REGN5458 as monotherapy in patients with relapsed or refractory Multiple Myeloma (MM) who have exhausted therapeutic options Phase 2: To assess the preliminary anti-tumor activity of REGN5458 The secondary.

Multiple myeloma MRI - wikidocNovel Agents for R/R MM - Expert Analysis - Myeloma - 2020NDA Submitted for Triple-Class Refractory Multiple MyelomaBest Multiple Myeloma Stock Photos, Pictures & Royalty

Melflufen Shows Positive Response in Triple-refractory

The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody The treatment has been recommended for use in in adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and a CD38-targeted antibody, and have progressed on their last therapy. 1

Integration of Novel Agents into the Care of Patients withNovel Experimental Drugs for Treatment of Multiple Myeloma

Preliminary Results of Ciltacabtagene Autoleucel in Treating Relapsed/Refractory Multiple Myeloma. Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma. Data from the preliminary phase 1b/2. Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will develop daratumumab-refractory disease, which carries a poor prognosis. Since daratumumab also has immunomodulatory effects, addition of the PD-L1 blocking antibody durvalumab at the time of progression may reverse daratumumab-resistance Myeloma Research News. Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with triple-refractory multiple myeloma to access the investigational medicine melflufen (melphalan flufenamide) before its approval. sEAPort (NCT04534322) is available to patients in the U.S. who.. REGN5458 monotherapy is being investigated in an open-label, phase I/II dose-escalation study in patients with relapsed or refractory (R/R) multiple myeloma who are at least triple refractory to. FDA Approves Pepaxto for Triple-Refractory Multiple Myeloma The FDA granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone for adults with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy and whose disease is refractory to Read mor